targeted-therapeutics
(4)
Ability Biotherapeutics
Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.
CatenaBio
CatenaBio is a UC Berkeley spinout building a next-generation bioconjugation platform for targeted cancer therapies. Its proprietary CysTyr platform uses an engineered enzyme, Catenase, to forge a site-specific bond between cysteine and tyrosine residues (the C-Y Bond) using only native amino acids. This lets the company attach multiple different drug payloads to a single antibody, producing Multi-Payload Conjugates (MPCs) designed to overcome tumor resistance where conventional single-payload ADCs fall short.
Solu Therapeutics
Solu Therapeutics is a Boston-based clinical-stage biotech building a new class of medicines that selectively kill disease-driving cells. Its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms fuse the precise binding of small molecules with the cell-killing power of antibodies, reaching cell-surface targets - like GPCRs and ion channels - that traditional antibodies cannot. Its lead program, STX-0712, is a CCR2-targeting candidate in a Phase 1 trial for chronic myelomonocytic leukemia and other advanced blood cancers.
Ampersand Biomedicines
Ampersand Biomedicines is a Boston-area biotech founded by Flagship Pioneering that builds programmable biologic medicines designed to act only where disease lives. Its computational Address, Navigate, Determine (AND) Platform maps the body for ideal localization targets and designs AND-Body Therapeutics that anchor at a disease site and conditionally switch on biology there, aiming to widen the therapeutic window and cut the off-tissue side effects that limit conventional drugs.